mk-2866 MK2866 Ostarine CAS: 1202044-20-9

CAS NO: 1202044-20-9
mk-2866 MK2866 Ostarine
Chemical Name: Ostarine(MK-2866)
Molecular Formula: C19H14F3N3O3
Formula Weight: 389.33
CAS No.: 1202044-20-9
Description Review
Description

MK-2866, also known as Ostarine, is a selective androgen receptor modulator (SARM) used in the medical research and bodybuilding communities. In this article, we will explore the properties, uses, potential benefits, and side effects of this product.

Chemical Properties The chemical name of MK-2866 is (2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide, and its molecular formula is C19H14F3N3O3. The compound has a formula weight of 389.33 g/mol and a CAS number of 1202044-20-9.

Top Ten Keywords and Synonyms

  1. Ostarine (brand name)
  2. Selective Androgen Receptor Modulator (SARM)
  3. Medical Research
  4. Muscle Wasting Treatment
  5. Bodybuilding
  6. Bone Density Improvement
  7. Testosterone Replacement Therapy
  8. Lean Muscle Mass Enhancement
  9. Joint Health
  10. Fat Loss

Health Benefits of MK-2866 MK-2866 has been shown to have potential health benefits, including muscle wasting treatment, lean muscle mass enhancement, bone density improvement, joint health, fat loss, and testosterone replacement therapy.

Potential Effects MK-2866 works by selectively binding to androgen receptors, leading to potential anabolic effects such as increased protein synthesis and muscle growth. Additionally, the compound may improve bone density and joint health. Studies suggest that MK-2866 may also have potential applications for treating muscle wasting disorders and promoting fat loss.

Product Mechanism MK-2866 works by selectively binding to androgen receptors, leading to potential anabolic effects such as increased protein synthesis and muscle growth. By targeting specific receptors, the compound may also prevent unwanted side effects associated with traditional anabolic steroids.

Safety MK-2866 is considered safe for use in medical research but should be handled with care and stored properly. Ingestion or inhalation of the product may cause irritation, respiratory distress, or other adverse effects. Proper protective measures should be taken when handling MK-2866.

Side Effects Few studies have explored the potential side effects of MK-2866 in humans, but animal studies suggest that the compound may cause mild gastrointestinal upset at high doses. Additionally, long-term use of SARMs may increase the risk of developing hormonal imbalances and other adverse effects.

Dosing Information The appropriate dosing information for MK-2866 varies depending on the intended use of the compound. In medical research and bodybuilding, dosages are typically determined based on the study objectives and individual needs.

Conclusion In conclusion, MK-2866 is a promising compound with potential benefits in various applications, including muscle wasting treatment, lean muscle mass enhancement, bone density improvement, joint health, fat loss, and testosterone replacement therapy. The compound works by selectively binding to androgen receptors, leading to potential anabolic effects without the unwanted side effects associated with traditional anabolic steroids. While the compound is generally considered safe for use in medical research, proper precautions should be taken when handling it to avoid adverse effects. With further research, scientists may uncover additional potential benefits of MK-2866, making it an even more valuable resource in various industries. However, it is important to note that the compound should only be used under the supervision of a qualified medical professional and is not approved for human consumption outside of medical research purposes

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code